help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on February 28, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-2710
A more recent version of this article appeared on May 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/5/1842    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalfa, N.
Right arrow Articles by Sultan, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalfa, N.
Right arrow Articles by Sultan, C.
Right arrowPubmed/NCBI databases
*OMIM
*Substance via MeSH
Medline Plus Health Information
*Ovarian Cancer

Submitted on December 13, 2005
Accepted on February 22, 2006

Activating Mutations of the Stimulatory G Protein (gsp) in Juvenile Ovarian Granulosa Cell Tumors: a New Prognostic Factor?

Nicolas Kalfa, Aude Ecochard, Catherine Patte, Pierre Duvillard, Francoise Audran, Catherine Pienkowski, Elisabeth Thibaud, Raja Brauner, Claudine Lecointre, Dominique Plantaz, Anne-Marie Guedj, Francoise Paris, Pierre Baldet, Serge Lumbroso, and Charles Sultan*

Unité d'Endocrinologie-Gynécologie Pédiatrique, Service de Pédiatrie 1, Hôpital Arnaud-de-Villeneuve, and Service d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie, CHU Montpellier, France.; INSERM U540, Hormones et Cancers, Montpellier, France.; Service d'Oncologie Pédiatrique, Institut Gustave Roussy, Villejuif, France; Service d'Anatomo-pathologie, Institut Gustave Roussy, Villejuif, France; Service d'Endocrinologie Pédiatrique, Hôpital des Enfants, CHU Toulouse, France; Service d'Endocrinologie Pédiatrique, Hôpital Necker, APHP, Paris, France; Service d'Endocrinologie Pédiatrique, Hôpital Kremlin-Bicêtre, APHP, Paris, France; Service d'Endocrinologie Pédiatrique, Hôpital Charles Nicolle, CHU Rouen, France; Service de Pédiatrie, CHU Grenoble, France; Service d'Endocrinologie, Hôpital Caremeau, CHU Nîmes, France; Service d'Anatomopathologie, Hôpital Lapeyronie, CHU Montpellier, France; (SL's present address: Laboratoire de Biochimie, CHU Nimes, France)

* To whom correspondence should be addressed. E-mail: c-sultan{at}chu-montpellier.fr.

Context: Conflicting data have been reported regarding the presence of a constitutive activation of G{alpha}s in ovarian granulosa cell tumors (OGCT). Although the precise role of this mutation in the transformation of ovarian cells into malignant cells remains debatable, it has been demonstrated in other tissues that the rate of cell proliferation and invasiveness can be influenced by the gsp oncogene.

Objective: To determine whether activating mutations of G{alpha}s or G{alpha}i are present in juvenile OGCTs and, if so, whether these mutations are significant prognostic factors.

Design and setting: Multicentric nationwide study.

Patients and methods: Thirty children with juvenile OGCT were included from the malignant germinal tumor protocol of the French Society for Childhood Cancer. Genetic studies of the tumoral DNA used nested PCR, laser microdissection and direct sequencing.

Results: G{alpha}s activating mutations in hot spot position 201 were found in 9 patients (30%). Laser microdissection confirmed that mutations R201C and R201H were exclusively localized in the tumoral granulosa cells and were absent in the ovarian stroma. Patients with a hyperactivated G{alpha}s exhibited a significantly more advanced tumor (P < 0.05) since 7 of them (77.7%) were staged as Ic or had had a recurrence. G{alpha}i did not exhibit any mutation.

Conclusions: 1. Activating mutations of G{alpha}s are present in 30% of juvenile ovarian granulosa cell tumors. 2. The gsp oncogene, which is known to be implicated in cell proliferation and tumoral invasiveness, can be considered as a new prognostic factor of these tumors.


Key words: Ovarian Neoplasms • Granulosa Cell Tumor • GTP-Binding Protein alpha-subunits • Gs • Mutation • Prognosis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society